Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

Rivoceranib (known in China as apatinib) is a selective vascular endothelial growth factor receptor‐2 (VEGFR‐2) tyrosine kinase inhibitor which inhibits angiogenesis in solid tumors. The aim of study was to evaluate potential pharmacokinetic (PK) differences between the Caucasian, Japanese, and Chin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Fundamental & clinical pharmacology 2021-04, Vol.35 (2), p.485-495
Hauptverfasser:	Sachar, Madhav, Park, Cheol Hee, Pesco‐Koplowitz, Luana, Koplowitz, Barry, McGinn, Arlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis inhibitors caucasians Chinese Enzyme inhibitors ethnic difference Genotypes Growth factors Japanese Kinases Oral administration Pharmacokinetics Pharmacology phase 1 Populations Protein-tyrosine kinase Rate constants Solid tumors Tumors Tyrosine Vascular endothelial growth factor Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!